BioCentury
ARTICLE | Politics, Policy & Law

Readout for Gilead’s remdesivir in COVID-19 could warrant emergency use authorization

BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.

April 29, 2020 2:12 PM UTC
Updated on May 1, 2020 at 9:21 PM UTC

Remdesivir is the new standard of care for COVID-19, NIAID director Anthony Fauci said Wednesday. Other treatments will be compared with Gilead’s antiviral, and the therapy will be combined with other investigational drugs including anti-inflammatory mAbs.

An Emergency Use Authorization from FDA to treat COVID-19 could be the next step for the Gilead Sciences Inc. (NASDAQ:GILD) antiviral, according to former FDA Commissioner Scott Gottlieb...

BCIQ Company Profiles

Gilead Sciences Inc.